Full Breakdown
Rising Drug Prices Amid Trump Administration's Pricing Deals
4/21/2026, 1:19:04 AM
Overview of the Current Situation
A recent U.S. Senate report, released by Senator Bernie Sanders, indicates that drug companies involved in pricing agreements with President Donald Trump have continued to increase prices on numerous medications. The report highlights that new drugs are launching at exorbitant prices, averaging around $353,000 annually. Notable price increases were observed for established medications, such as Merck’s cancer drug Keytruda, which rose by 6% to approximately $210,000 per year, and Novartis’ multiple sclerosis drug Kesimpta, which increased by nearly $10,500 to about $141,000 annually.
Key Findings from the Senate Report
The report details significant price hikes for various treatments, including Bristol Myers Squibb’s Opdivo, which rose 4% to about $260,000 annually. Newer therapies are even more costly, with Johnson & Johnson’s Inlexzo priced at around $1 million and Novartis’ Zolgensma reaching over $2.5 million for a single dose. These findings raise questions regarding the effectiveness of the administration's "most favored nation" (MFN) pricing approach, which aims to align U.S. drug prices with those in other wealthy nations.
Official Statements & Responses
Stacie Dusetzina, a health policy professor, criticized the lack of transparency in the administration's pricing deals, suggesting they primarily benefit drug companies. In contrast, White House spokesperson Kush Desai defended the administration's approach, stating that the report focuses on list prices, which do not reflect actual costs paid by patients. Antonio Ciaccia, CEO of the nonprofit 46brooklyn, noted that many drugs excluded from the pricing deals have seen little to no change, indicating a continuation of business as usual.
Criticism & Opposition
Critics argue that the MFN policy, intended to lower drug prices, may inadvertently strengthen large pharmaceutical companies while hindering smaller firms. Analysts warn that the policy could lead to increased market concentration, making it difficult for smaller companies to compete. A coalition of over 50 center-right organizations has expressed concerns that MFN could suppress innovation and reduce U.S. competitiveness in the global market.
Conflicting Reports & Gaps
While the Senate report emphasizes rising drug prices, some industry analysts suggest that the MFN policy may have led to lower prices for certain off-patent drugs. However, the full terms of the agreements between the Trump administration and drug manufacturers remain undisclosed, leading to uncertainty about the policy's overall impact.
What's Next
As the debate over drug pricing continues, lawmakers, including Democrats, have called for the release of complete details regarding the MFN deals. The lack of transparency could hinder discussions on whether these agreements effectively lower prescription drug prices for Americans. The ongoing scrutiny of the MFN policy will likely shape future legislative efforts aimed at addressing drug affordability.
Verbatim Quotes
“American people continue to pay by far the highest prices in the world for prescription drugs,” — Senator Bernie Sanders
“Once you dig into the details, it appears that the administration’s efforts to date have mostly served to help drug companies,” — Stacie Dusetzina, Health Policy Professor
“This represents the greatest victory for patient affordability in the history of American healthcare, by far,” — President Donald Trump
“Policymakers need to consider whether MFN could inadvertently increase concentration even as it attempts to reduce prices.” — Anthony Lo Sasso, Professor at the University of Wisconsin-Madison
